Prasugrel versus clopidogrel for acute coronary syndromes without revascularization
Reads0
Chats0
About:
This article is published in Indian heart journal.The article was published on 2013-03-01 and is currently open access. It has received 272 citations till now. The article focuses on the topics: Prasugrel & Clopidogrel.read more
Citations
More filters
Journal ArticleDOI
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).
Borja Ibanez,Stefan James,Stefan Agewall,Manuel J. Antunes,Chiara Bucciarelli-Ducci,Héctor Bueno,Alida L.P. Caforio,Filippo Crea,John A. Goudevenos,Sigrun Halvorsen,Gerhard Hindricks,Adnan Kastrati,Mattie J. Lenzen,Eva Prescott,Marco Roffi,Marco Valgimigli,Christoph Varenhorst,Pascal Vranckx,Petr Widimský +18 more
TL;DR: 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation are published.
Journal ArticleDOI
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Glenn N. Levine,Eric R. Bates,John A. Bittl,Ralph G. Brindis,Stephan D. Fihn,Lee A. Fleisher,Christopher B. Granger,Richard A. Lange,Michael J. Mack,Laura Mauri,Roxana Mehran,Debabrata Mukherjee,L. Kristin Newby,Patrick T. O'Gara,Marc S. Sabatine,Peter K. Smith,Sidney C. Smith +16 more
TL;DR: Jonathan L. Halperin, MD, FACC, FAHA, Chair Glenn N. Levine, MD; Sana M. Al-Khatib,MD; and Lesley H. Curtis, PhD, PhD are the current members of the FACC/FAHA Board of Directors.
Journal ArticleDOI
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.
Borja Ibanez,Borja Ibanez,Stefan James,Stefan Agewall,Manuel J. Antunes,Chiara Bucciarelli-Ducci,Héctor Bueno,Alida L.P. Caforio,Filippo Crea,John A. Goudevenos,Sigrun Halvorsen,Gerhard Hindricks,Adnan Kastrati,Mattie J. Lenzen,Eva Prescott,Marco Roffi,Marco Valgimigli,Christoph Varenhorst,Pascal Vranckx,Petr Widimský +19 more
TL;DR: 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation are published, and the standard of care for these patients is considered to be good.
Journal ArticleDOI
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.
Marco Valgimigli,Héctor Bueno,Robert A. Byrne,Jean-Philippe Collet,Francesco Costa,Anders Jeppsson,Peter Jüni,Adnan Kastrati,Philippe Kolh,Laura Mauri,Gilles Montalescot,Franz-Josef Neumann,Mate Peticevic,Marco Roffi,Philippe Gabriel Steg,Stephan Windecker,José Luis Zamorano +16 more
TL;DR: Authors/Task Force Members: Marco Valgimigli* (Chairperson) (Switzerland), Héctor Bueno (Spain), Robert A. Byrne (Germany), Jean-Philippe Collet (France), Francesco Costa (Italy), Anders Jeppsson (Sweden), Peter Jüni (Canada), Adnan Kastrati ( Germany), Philippe Kolh (Belgium), Laura Mauri (USA), Gilles Montalescot (France).
Journal ArticleDOI
Rivaroxaban in Peripheral Artery Disease after Revascularization
Marc P. Bonaca,Rupert Bauersachs,Sonia S. Anand,E Sebastian Debus,Mark R. Nehler,Manesh R. Patel,Fabrizio Fanelli,Warren H. Capell,Lihong Diao,Nicole Jaeger,Connie N. Hess,Akos F. Pap,John Kittelson,Ivan Gudz,Lajos Mátyás,Dainis Krievins,Rafael Diaz,Marianne Brodmann,Eva Muehlhofer,Lloyd Haskell,Scott D. Berkowitz,William R. Hiatt +21 more
TL;DR: In patients with peripheral artery disease who had undergone lower-extremity revascularization, rivaroxaban at a dose of 2.5 mg twice daily plus aspirin was associated with a significantly lower incidence of the composite outcome of acute limb ischemia, major amputation for vascular causes, myocardial infarction, ischemic stroke, or death from cardiovascular causes than aspirin alone.
References
More filters
Journal ArticleDOI
Platelet Function During Extended Prasugrel and Clopidogrel Therapy for Patients With ACS Treated Without Revascularization: The TRILOGY ACS Platelet Function Substudy
Paul A. Gurbel,David Erlinge,E. Magnus Ohman,Benjamin Neely,Megan L. Neely,Shaun G. Goodman,Kurt Huber,Mark Y. Chan,Jan H. Cornel,Eileen Brown,Chunmei Zhou,Joseph A. Jakubowski,Harvey D. White,Keith A.A. Fox,Dorairaj Prabhakaran,Paul W. Armstrong,Udaya S. Tantry,Matthew T. Roe +17 more
TL;DR: Among patients with ACS without ST-segment elevation and initially managed without revascularization, prasugrel was associated with lower platelet reactivity than clopidogrel, irrespective of age, weight, and dose.
Journal ArticleDOI
Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial.
David Erlinge,Jurriën M. ten Berg,David P. Foley,Dominick J. Angiolillo,Henrik Wagner,Patricia B. Brown,Chunmei Zhou,Junxiang Luo,Joseph A. Jakubowski,Brian A. Moser,David S. Small,Thomas O. Bergmeijer,Stefan James,Kenneth J. Winters +13 more
TL;DR: In aspirin-treated patients with CAD, prasugrel 5 mg in LBW patients reduced platelet reactivity to a similar extent as pr asugrel 10 mg in HBW patients and resulted in greater platelet inhibition, lower HPR, and similar bleeding rates compared with clopidogrel.
Journal ArticleDOI
Prasugrel 5 mg in low body weight patients reduces platelet reactivity to a similar extent as prasugrel 10 mg in higher body weight patients: results from the feather trial
David Erlinge,Jurrien Ten Berg,David Foley,D. J. Angiolillo,Patricia Brown,Henrik Wagner,Chunmei Zhou,Joe T Jakubowski,Thomas O. Bergmeijer,Stefan James,Kenneth John Winters +10 more
TL;DR: In the TRITON trial prasugrel 10 mg reduced ischemic events vs. clopidogrel 75 mg but increased bleeding, notably in patients with low body weight (LBW, <60 kg).